Toxic Epidermal Necrolysis Associated with Interleukin-2

Abstract

The use of IL-2 in bedridden patients with performance status >2 must be given on an individualized basis. If radiotherapy over extensive areas of the body is needed, the use of IL-2 must be postponed until radiotherapy is completed.